e2ac493b-9157-4756-8949-edf4b7f334cd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- ANDROGEN_RESPONSE+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- COAGULATION+0.200
- FATTY_ACID_METABOLISM+0.200
- GLYCOLYSIS+0.200
- HEDGEHOG_SIGNALING+0.200
- PEROXISOME+0.200
- UV_RESPONSE_DN+0.200
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- APOPTOSIS-0.200
- INFLAMMATORY_RESPONSE-0.200
- INTERFERON_ALPHA_RESPONSE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- MYC_TARGETS_V1-0.200
- MYC_TARGETS_V2-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7421-01A-11R-2081-07 | — | — | 0.816 |
| 2 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.802 |
| 3 | SRR8613754 | — | F | 0.791 |
| 4 | TCGA-B6-A1KI-01A-11R-A14M-07 | — | B | 0.770 |
| 5 | SRR8518146 | — | F | 0.770 |
| 6 | TCGA-44-7671-01A-11R-2066-07 | — | cohortA2 | 0.756 |
| 7 | C3N-01021 | — | cohortA1 | 0.751 |
| 8 | TCGA-A2-A0EM-01A-11R-A034-07 | — | B | 0.750 |
| 9 | SRR8518184 | — | F | 0.750 |
| 10 | TCGA-AN-A0FS-01A-11R-A034-07 | — | A | 0.745 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |